Aug
2009

Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.

Hadland BK, Longmore GD
J Clin Oncol 2009;27(25):4217-4226.
NATA Rating :
Review by :
NATA Review

The discussion regarding benefits and harms of erythropoiesis-stimulating agents (ESAs) in oncology is ongoing, with conflicting data from numerous studies. The review by Hadland and Longmore on this topic covers the existing literature in an organized, detailed and unbiased manner. Of particular interest is the discussion on potential mechanisms leading to tumor progression and decreased survival in oncology patients treated with ESAs. The article is worth reading.

– alice Maniatis